HealthMore in Health→
Roche’s oral MS candidate extends relapse-free time, but safety questions remain
Key Takeaways
- Roche’s oral MS candidate more than doubled relapse-free interval versus Aubagio, according to conference data.
- The drug is described as a BTK inhibitor, a class under close watch in neuroinflammatory disease.
- Potential liver toxicity could shape how regulators and clinicians evaluate the treatment.
DE
DT Editorial Team··via endpoints.news